Yili Chuanning Biotechnology Co.,Ltd. (SHE:301301)

Market Cap	27.50B
Revenue (ttm)	5.53B
Net Income (ttm)	1.34B
Shares Out	2.23B
EPS (ttm)	0.60
PE Ratio	20.55
Forward PE	17.74
Dividend	0.27 (2.18%)
Ex-Dividend Date	Jun 10, 2025

Volume	32,325,223
Average Volume	22,546,204
Open	12.66
Previous Close	12.24
Day's Range	12.22 - 12.66
52-Week Range	10.41 - 16.58
Beta	0.16
RSI	51.81
Earnings Date	Aug 26, 2025

About SHE:301301

Yili Chuanning Biotechnology Co.,Ltd. engages in the research and development, and industrialization of biological fermentation technology in China. The company offers antibiotic intermediates, such as erythromycin thiocyanate, penicillin G potassium salt, 6-aminopenicillanic acid, 7-aminocephalosporanic acid, 7-aminodesacetoxycephalosporanic acid, and ursodeoxycholic acid. Yili Chuanning Biotechnology Co.,Ltd. was incorporated in 2010 and is based in Yining, China. Yili Chuanning Biotechnology Co.,Ltd. operate as a subsidiary of Sichuan Kelun ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 3,184
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 301301

Financial Performance

In 2024, SHE:301301's revenue was 5.76 billion, an increase of 19.38% compared to the previous year's 4.82 billion. Earnings were 1.40 billion, an increase of 48.88%.